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Abstract
Objective: To investigate the impact of antiretroviral therapy (ART) on long-term population-level tuberculosis disease (TB)
incidence in sub-Saharan Africa.
Methods: We used a mathematical model to consider the effect of different assumptions about life expectancy and TB risk
during long-term ART under alternative scenarios for trends in population HIV incidence and ART coverage.
Results: All the scenarios we explored predicted that the widespread introduction of ART would initially reduce population-
level TB incidence. However, many modelled scenarios projected a rebound in population-level TB incidence after around
20 years. This rebound was predicted to exceed the TB incidence present before ART scale-up if decreases in HIV incidence
during the same period were not sufficiently rapid or if the protective effect of ART on TB was not sustained. Nevertheless,
most scenarios predicted a reduction in the cumulative TB incidence when accompanied by a relative decline in HIV
incidence of more than 10% each year.
Conclusions: Despite short-term benefits of ART scale-up on population TB incidence in sub-Saharan Africa, longer-term
projections raise the possibility of a rebound in TB incidence. This highlights the importance of sustaining good adherence
and immunologic response to ART and, crucially, the need for effective HIV preventive interventions, including early
widespread implementation of ART.
Citation: Dodd PJ, Knight GM, Lawn SD, Corbett EL, White RG (2013) Predicting the Long-Term Impact of Antiretroviral Therapy Scale-Up on Population
Incidence of Tuberculosis. PLoS ONE 8(9): e75466. doi:10.1371/journal.pone.0075466
Editor: Hiroshi Nishiura, The University of Tokyo, Japan
Received January 14, 2013; Accepted August 18, 2013; Published September 17, 2013
Copyright:  2013 Dodd et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: PJD is funded by the Consortium to Respond Effectively to the AIDS/TB Epidemic (19790.01) grant from the Bill and Melinda Gates Foundation. SDL and
ELC are funded by the Wellcome Trust, London, UK. RGW is funded by a Medical Research Council (UK) Methodology Research Fellowship (G0802414), grant (MR/
J005088/1), and the Consortium to Respond Effectively to the AIDS/TB Epidemic (19790.01) grant from the Bill and Melinda Gates Foundation (21675). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: peter.dodd@lshtm.ac.uk
Introduction
It is estimated that 79% of the global burden of HIV-associated
tuberculosis disease (TB) occurs within sub-Saharan Africa [1].
Control of this epidemic requires not only TB case finding and
effective treatment, but also preventive interventions including
antiretroviral therapy (ART), isoniazid preventive therapy, inten-
sified case finding and infection control [2]. Among these
interventions, ART is the key tool, profoundly reducing all-cause
mortality. ART reduces TB incidence rates in HIV cohorts over
the short-term by approximately two-thirds, and this effect is
observed across a broad range of baseline CD4 cell counts and
independent of tuberculin skin test status [3–5]. Time-dependent
reductions in incidence rates are strongly associated with the CD4
cell count response to ART [6,7]. Short-term benefits in TB
notification rates at the population level have also been observed
in communities in South Africa and Malawi where ART has been
scaled up rapidly [8,9].
Despite these promising short-term observations, the long-term
impact of ART scale-up on TB incidence rates at the population
level remains unknown and will depend on a number of factors.
TB rates after 8 years of follow-up in a South African ART cohort
remained several-fold higher than those in non-HIV-infected
people in the same community, even among those with the
greatest CD4 cell count recovery [10]. Longer-term responses to
ART are unknown but as ART services have expanded over time,
reports from the region describe increasing rates of programme
loss to follow-up and virological failure [11,12]. Thus, individuals
receiving ART are likely to retain a high cumulative lifetime risk of
TB. Compounded by rising HIV prevalence resulting from
increased life expectancy with ART scale-up, and ongoing HIV
transmission, these factors could collectively result in a rebound in
population level TB incidence rates in the long-term.
The potential for a rebound in TB incidence may be offset by
decreases in HIV incidence, either due to the natural dynamics of
the HIV epidemic or to preventive interventions including ART.
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e75466
There is now much interest in the potential for widespread scale-
up of early ART (or universal test and treat) to reduce HIV
incidence [13,14]. This strategy could also reduce TB incidence
due to the combined effects of short-term CD4 recovery and long-
term reductions in HIV incidence [5,15].
No empirical studies have yet measured the long-term dynamics
of protection from TB in individuals on ART, nor the impact of
combinations of ART and other HIV-prevention measures on
population-level HIV-incidence. We therefore investigated how
uncertainty in these variables is reflected in long-term population-
level TB trends, using a mathematical model that separates the
contributions from each.
Methods
We used deterministic partial differential equations to model
a population of HIV-infected individuals, as HIV incidence
declined exponentially, and coverage of ART increased. Time-
since-infection, age and CD4 cell count are tracked through
calendar time, with a variable proportion of those reaching a
threshold CD4 count beginning ART (Figure 1). Reinfection,
reactivation and primary routes to TB disease are included as an
average, under the assumptions that the TB force-of-infection is
constant and that each route is affected by HIV in the same way.
HIV incidence is modelled as an independent function of time,
and TB incidence in HIV-uninfected individuals is not modelled
explicitly.
The age of HIV infection is modelled by a Weibull distribution
with shape parameter k = 2.3 and scale s = 25.9 years matching
the gender-average of data presented in Stover et al. 2010 [16]. Life
expectancy without ART is modelled by a Weibull distribution
with parameters (k = 2.3, s = 13.3 years), from a weighted least-
squares fit to the survival data from the CASCADE collaboration
[17]. The CD4 cell count trend and rate ratio for developing TB
in HIV-infected individuals not receiving ART are modelled
similarly to Williams et al. [15]. Upon infection, CD4 cell count
drops by 25% from an initial value of 1000 cells per microliter,
followed by a linear decline to zero at death. Individuals’ TB
incidence rate increases exponentially with decreasing CD4 cell
count with a rate 0.36 per 100 cells per microliter.
ART is assumed to start only when individuals reach a
threshold CD4 count (CD4A= 225 cells per microliter in default
scenarios; 100, 350 and 500 cells per microliter scenarios in
Figures S5 and S6 in Materials S1), and ART scale-up is modelled
by an exponential decline through calendar time, t, in the
proportion of individuals who do not start ART when they pass
this threshold, with no one receiving ART at t = 0 (Figure S4 in
Materials S1). Those already having CD4 counts below the
threshold at t = 0 do not receive ART. Our default ART scale-up
occurred over 5 years. TB risk by CD4 count is assumed to be the
same on and off ART. As our primary focus is the long-term
consequences, we assume the two year immune recovery on
starting ART reported in [18,19] is approximated by an
instantaneous increase in CD4 count to a level compatible with
observations of TB risk on ART after CD4 cell count recovery has
occurred, i.e. so that the incidence rate ratio (IRR) for HIV-
infected vs. HIV-uninfected is 4.4 [10], corresponding to a CD4
count of 588 cells per microliter (Figure 1B, CD42). The ratio of
the TB rate just after ART initiation to the rate, R, just before
ART initiation is denoted a. For an averaged representation of
waning protection from TB due to immunologic failure and
imperfect adherence, we allow TB incidence to increase
exponentially while on ART, varying between our optimistic
scenario (f=0, blue lines in Figure 1), which has perfectly
maintained protection on ART, and our pessimistic scenario
(f=1, red lines in Figure 1). The corresponding mean CD4 count
of cohorts after starting ART is shown with matching colors in
Figure 1B: f represents the fractional CD4 decline from post-ART
immune recovery to death.
Life expectancy on ART is influenced by age and CD4 cell
count [20,21]. We model life expectancy as (60-age). lp where age is
the current age, and l the fraction of life expectancy remaining
when starting ART (a measure of CD4 depletion in the model).
The parameter p controls how strongly late ART initiation reduces
life expectancy from the level of HIV-uninfected individuals, and
is taken to be 0.5 in the default scenario (see Figure S1 in Materials
S1). When p,1, there is a stronger influence of a low CD4 count
at ART start on life expectancy compared with a high CD4 count;
increasing p results in shorter life expectancy (see Figure S2 in
Materials S1).
Given the above assumptions about CD4 decline by time-
since-infection and the effect of ART on TB rates and life
expectancy, the partial differential equations describing TB
incidence in a cohort with specified age at HIV infection and
HIV life expectancy without ART were solved analytically. To
compute TB incidence for a population with distributions of HIV
life expectancy and age at infection, averages over the Weibull
distributions describing these variables’ statistical variability were
calculated by Monte Carlo methods to within an accuracy of
,1%, using the R statistical package [22] (see Materials S1 for
more details). To ensure conclusions were not influenced by
secular trends, we started the model from an equilibrium with
constant HIV and TB incidences, and a constant birth rate. 50
year TB incidence time-series were generated for scenarios with
0% and 10% per year rates of decline in HIV incidence. Peak and
cumulative TB incidence over 50 years were explored as the
decline in HIV incidence varied from 0% to 25% per year and the
long-term protection on ART varied from perfect to zero efficacy.
Sensitivity of these outputs to uncertainties in the durability of
protection on ART and life expectancy on ART was considered
by varying parameters f and p from 0 to 1.
Results
Model predictions of TB incidence relative to its value before
ART scale up (t = 0, Figure 2A) show that with ultimately complete
ART coverage and hence lower individual TB incidence rates,
total TB incidence would initially decrease in all four depicted
scenarios (blue for optimistic and red for pessimistic scenarios in all
figures). In the two scenarios where HIV incidence remains
constant (dashed lines in Figure 2A), TB incidence tends towards a
new equilibrium whose value is only dependent on the total
lifetime risk of developing TB (see Figure S3 and associated
explanation in Materials S1). Whether this equilibrium is higher or
lower than the initial TB incidence is completely determined by
comparing the size of the hatched areas in Figure 1C. This
captures the competing effects of the extended life-span and
reduced hazard of TB whilst on long-term ART. In the two
scenarios where HIV incidence is falling at 10% per year (solid
lines in Figure 2A) the TB incidence in HIV-infected people must
also eventually tend to zero because the size of the HIV-infected
population falls to zero. Thus in scenarios that assume a 10% per
year decline in HIV incidence (solid lines in Figure 2A) there is
competition between the trend towards a higher equilibrium and
the reduction in HIV incidence. Under pessimistic assumptions
about maintenance of immune status and hence protection from
TB on ART (red solid line in Figure 2A), even large rates of
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decline in HIV incidence may not prevent a higher peak rebound
in population TB incidence in the future (seen here after 30 years).
The cumulative incidence of TB over 50 years could remain
unchanged by the introduction of ART if the increase in HIV
prevalence is balanced by the lower individual TB rates. This
balance is quantitatively mapped in Figure 2B: areas below the
solid colored lines (blue for the optimistic scenario, red for the
pessimistic), where protection is better (lower y-values), or HIV
decline faster (higher x-values), correspond to regions where the
cumulative TB incidence is reduced over 50 years. Most scenarios
correspond to reductions in cumulative TB incidence when
assumptions about durability of protection on ART are optimistic,
and for earlier CD4 thresholds for ART initiation (see Figure S5 in
Materials S1). This conclusion is robust to plausible variations in
life expectancy assumptions (shaded regions bounded by dashed
lines).
Similar calculations (Figure S2C and Figure S6 in Materials S1)
determine when any peak in TB incidence over 50 years is higher
or lower than the initial rate. A lower peak incidence is found to be
less common than a reduction in cumulative incidence (a smaller
area beneath the solid lines), particularly for scenarios with waning
protection.
Discussion
Our model predicted that extensive ART roll-out will initially
reduce TB incidence, but that total TB incidence may under
certain circumstances increase after approximately 20 years, when
reductions in HIV-associated mortality lead to increased lifetime
risks of TB. This subsequent peak in TB incidence may exceed TB
incidence before ART roll-out in scenarios with waning protection
on ART or slowly declining HIV incidence. Cumulative TB
incidence over 50 years is predicted to be lower with ART in most
scenarios where HIV incidence declined by more than 10% per
year. This suggests that in order to decrease TB incidence in the
Figure 1. Model structure and assumptions. A. Schematic of
modelled progression from HIV infection to death. People living
with HIV are modelled using a continuous time-since-infection. Their
time-of-death without ART, is drawn from a Weibull distribution, which
determines their rate of CD4 cell count decline (see Figure 1B). When
CD4 cell count reaches some threshold value CD4A individuals may start
ART with probability determined by the coverage at this calendar-time,
in which case their time-of-death is postponed to a time dependent on
their age and CD4 count and their CD4 count dynamics altered (see
Figure 1B). B. Model of CD4 positive lymphocyte count by time
since HIV infection. CD4 counts (cells per microliter) are assumed to
begin at CD40 = 1000, drop by 25% upon infection, and decline linearly
to zero at death in the absence of treatment. ART begins at a threshold
CD4A and is modelled as instantaneously increasing CD4 cell count to
the level achieved after immune reconstitution has plateaued, CD42. To
explore the uncertainty in the durability of this recovery due to
treatment failure and loss to follow-up, the mean cohort CD4 cell count
is assumed to linearly decline resulting in the loss of a fraction f of CD42
on death. The optimistic (blue line, f=0) corresponds to fully maintained
CD4 recovery. The pessimistic (red line, f= 1) corresponds to the
eventual complete loss of CD4 cells. C. The model of the TB
incidence rate ratio (IRR) by time since HIV infection. The IRR for
TB (relative those not infected by HIV) is taken to increase exponentially
with loss of CD4 count, from an initial value of around 2.5 caused by the
initial CD4 drop. The increase in CD4 count associated with starting ART
reduces the IRR by a factor a, from R (just before ART) to a value of 4.4,
in line with [10]. The red and blue lines correspond to the pessimistic
and optimistic CD4 trajectories shown in the same colors in Figure 1B.
The area with forward-slanting hatching is the lifetime risk of TB on ART;
the area with backward-slanting hatching is the lifetime risk of TB for an
individual who does not start ART.
doi:10.1371/journal.pone.0075466.g001
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long-term, HIV preventative strategies such as universal ‘test and
treat’ may be key to controlling the HIV-associated TB epidemic.
Our modelling complements that of Williams et al. [15] in
exploring ranges for key quantities. We vary changes in HIV
incidence independently from ART coverage, allowing for more or
less effective control of HIV; we consider a range of effects of ART
on immune status and the greatest number of people starting long-
term ART.ighest prevalence of HIV in[4]; we explore waning
protection and different life expectancies on ART, reflecting long-
term uncertainties at the individual and programmatic level.
We modelled rates of CD4 decline as correlated with mortality
(the random variable for CD4 decline rate was a function of that
modelling life expectancy). However our scenario explorations
allow the durability of TB protection and the reduction in
mortality from ART to vary independently. It may be more
realistic to consider longer life expectancies linked to better
sustained TB protective effect, and vice versa. In this case,
parameter combinations with higher values for both p and f (the
regions towards the lower extent of the blue-, and the upper extent
of the red-shaded areas in Figures 2 B&C) would be most relevant.
Proportional declines in HIV incidence of more than 5-10% per
year would then be sufficient to reduce cumulative TB incidence
among people living with HIV, but not to avoid a substantial
increase in TB incidence after around 20 years. Such an increase
need not imply a concomitant increase in mortality if TB
monitoring and treatment programs for those on ART are
functioning sufficiently well. Measures that further reduce the risk
of TB, such as isoniazid preventive therapy (IPT) for those with
HIV [23–25], may have a role in countering any rebound in
incidence. IPT added to ART has been shown to further reduce
TB rates by a supplementary factor of around 0.31–0.63
[23,24,26] but without a further large increment to life expectan-
cy. The long-term durability of this effect is unknown, but
sustained suppression was observed when IPT was given in
combination with ART continuously over 3 years [25]. In Figures
Figure 2. Results from the model. A. TB incidence dynamics.
Annual population-level TB incidence among HIV-infected persons
relative to the value before ART scale up. ART coverage, with initiation
at CD4 count of 225 cells per microliter, is assumed to increase from 0%
to 100% over 5-years. Blue and red lines correspond to the pessimistic
and optimistic scenarios of Figures 1B & C. Dashed lines assume no
drop in HIV incidence; solid lines correspond to an HIV incidence
declining at a proportional rate of 10% per year. B. Contours
separating regions where cumulative TB incidence over 50
years is increased from regions where it is decreased, as the
level of protection against TB conferred by ART (IRR) and the decline in
HIV incidence vary. The solid colored lines correspond to the default
dependence of life expectancy on CD4 count at ART initiation (i.e.
p= 0.5, see main text). Regions below these lines correspond to
decreases in cumulative incidence; above the lines to increases. Red and
blue lines correspond to the optimistic and pessimistic scenarios as
shown in Figures 1B & C and described in the text. The shaded regions
bounded by dashed lines indicate the variation of the contours of zero
change for cumulative incidence as the dependency of life expectancy
on CD4 count at ART initiation is varied (p ranging from 0.25 to 1).
Contours sweep from the lower dashed line for longer life expectancies
to the upper dashed line at shorter life expectancies. The horizontal
black dotted line represents the level of protection after CD4 recovery
corresponding to Figures 1B & C, i.e. to a= 0.24 for those started at
CD4A = 225 cells per microliter. C. Contours separating regions
where peak TB incidence over 50 years is higher than baseline
from regions where it is lower, as the level of protection against TB
conferred by ART (IRR) and the decline in HIV incidence vary. The
conditions and interpretation are as for Figure 2B, but with the
outcome being peak rather than cumulative TB incidence over 50 years:
the areas below the lines correspond to situations where the peak
incidence does not exceed baseline.
doi:10.1371/journal.pone.0075466.g002
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2B and C, the effect on a given choice of protection and HIV
decline of adding continuous IPT to ART can therefore be
assessed by reducing the IRR (y-value) by this factor. This implies
a substantial decrease in the range of parameters for which
cumulative TB incidence or peak TB incidence would increase.
Earlier ART initiation may also avoid this, depending on the
relative protection from TB afforded at higher CD4 counts, as well
as the effect on HIV-incidence.
This model assumes a fixed annual risk of tuberculosis infection
(ARTI) and does not account for potential changes over time,
for example reductions due to improved control of TB among
HIV-uninfected individuals. Including TB transmission from
HIV-infected individuals would tend to exaggerate both the
increases and decreases in TB incidence predicted by this model. It
is likely, however, that HIV-infected individuals contribute a small
proportion of the ARTI due to the lower rates of smear-positivity
[27–29] and a shorter duration of disease [27,30,31]. Once
relevant data become available, future modelling may need to
consider different characteristics for HIV-related TB in those on
ART, such as different rates of smear positivity and detection.
This paper has focused on long-term trends in TB incidence
rather than overall health outcomes, which we do not imply would
be worsened by ART scale-up. These data will be particularly
relevant for understanding potential trends in TB rates in the
countries in southern Africa, which have the highest prevalence of
HIV in the world, the highest TB incidence rates, and the greatest
number of people starting long-term ART. Our results do not
imply that ART scale-up would be disadvantageous, but rather
that the possibility of future increases in TB incidence may require
bolstering of TB control efforts.
In summary, this model described the potential for ART
scale-up to be associated with a rebound in long-term population
TB incidence rates driven by increased life expectancy in PLHIV.
This highlights the importance of sustaining good long-term
immunovirological responses to ART, use of adjunctive TB
preventive interventions and reducing HIV incidence with, for
example, a strategy of universal test and treat that would offer
further opportunities for integrated control.
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